BSYI
Biosyntech Inc
Price:  
0.00 
USD
Volume:  
21,000.00
Canada | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BSYI WACC - Weighted Average Cost of Capital

The WACC of Biosyntech Inc (BSYI) is 7.2%.

The Cost of Equity of Biosyntech Inc (BSYI) is 7,864.40%.
The Cost of Debt of Biosyntech Inc (BSYI) is 9.75%.

Range Selected
Cost of equity 1,737.30% - 13,991.50% 7,864.40%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 7.00% - 12.50% 9.75%
WACC 5.2% - 9.3% 7.2%
WACC

BSYI WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 376.83 2497.61
Additional risk adjustments 0.0% 0.5%
Cost of equity 1,737.30% 13,991.50%
Tax rate 26.20% 27.00%
Debt/Equity ratio 74415.12 74415.12
Cost of debt 7.00% 12.50%
After-tax WACC 5.2% 9.3%
Selected WACC 7.2%

BSYI's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BSYI:

cost_of_equity (7,864.40%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (376.83) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.